Major Investor Files to Sell $113M in TNGX Stock, Following $105M in Recent Sales
TNGX has more than doubled off its 52-week low of $4.6.
Summary
A former affiliate and major investor, Nextech Crossover I SCSp, has filed to sell an additional $113.4 million in Tango Therapeutics stock, following $105.1 million in sales over the past three months.
Key Events · Ownership and Investor Activity · TNGX
-
Major Investor Files to Sell
Nextech Crossover I SCSp, identified as a former affiliate, has filed a Form 144 to sell 3,766,081 shares of common stock.
-
Significant Proposed Sale Value
The proposed sale is valued at approximately $113,359,038.00, representing 2.15% of the company's market capitalization.
-
Follows Recent Large Sales
This filing follows sales of 3,500,000 shares for gross proceeds of $105,052,300.00 by the same entity within the last three months.
-
Substantial Liquidation
The combined sales and proposed sales by Nextech Crossover I SCSp total over $218 million, indicating a significant reduction of their stake in the company.
Analysis · TNGX · Life Sciences
Nextech Crossover I SCSp, a former affiliate and significant investor, has filed to sell an additional $113.4 million worth of Tango Therapeutics stock. This follows recent sales of $105.1 million by the same entity in the past three months, indicating a substantial and ongoing liquidation of their position. This large-scale selling by a major investor, especially after recent positive clinical data and a significant public offering, can create considerable selling pressure and suggests a lack of long-term conviction at current valuations.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNGX was trading at $31.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $4.60 to $34.39. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.